

2025 ASCO[®] ANNUAL MEETING



Dra. Beatriz García Paredes

Servicio de Oncología. Hospital Clínico San Carlos de Madrid. Instituto de Investigación
Hospital Clínico San Carlos (IdISSC). Universidad Complutense, Madrid

TITULARES EN TUMORES HEPATOBILIARES

Resumen en vídeo

Resumen en texto

AIO/CALGP/ACO-GAIN

Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the phase III AIO/CALGP/ACO-GAIN-Trial

[Ver Abstract](#)

POLCAGB

A phase III randomized clinical trial evaluating perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB)

[Ver Abstract](#)

GEMINI-Hepatobiliary

First-line rilvegostomig (rilve) plus chemotherapy (CTx) in advanced biliary tract cancer (BTC): Primary analysis of GEMINI-Hepatobiliary substudy 2 Cohort A

[Ver Abstract](#)



GRUPO DE TRATAMIENTO
DE LOS TUMORES DIGESTIVOS

2025 ASCO[®] ANNUAL MEETING



Dra. Beatriz García Paredes

Servicio de Oncología. Hospital Clínico San Carlos de Madrid. Instituto de Investigación
Hospital Clínico San Carlos (IdISSC). Universidad Complutense, Madrid

TITULARES EN TUMORES HEPATOBILIARES

Resumen en vídeo

Resumen en texto

ABSTRACT 4078

Clinical implication of MDM2 amplification in advanced biliary tract cancer (BTC): A propensity score-matched, retrospective cohort study of 813 patients

[Ver Abstract](#)

SHATA-001

Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: An update on SHATA-001 study

[Ver Abstract](#)

ABSTRACT 4088

**Efficacy and safety of regorafenib combination with PD-1 inhibitors vs. regorafenib monotherapy in second-line treatment for patients with unresectable hepatocellular carcinoma after failure of different first-line treatments:
A multicenter retrospective real-world study**

[Ver Abstract](#)



GRUPO DE TRATAMIENTO
DE LOS TUMORES DIGESTIVOS

2025 ASCO[®] ANNUAL MEETING



Dra. Beatriz García Paredes

Servicio de Oncología. Hospital Clínico San Carlos de Madrid. Instituto de Investigación
Hospital Clínico San Carlos (IdISSC). Universidad Complutense, Madrid

TITULARES EN TUMORES HEPATOBILIARES

Resumen en vídeo

Resumen en texto

ABSTRACT 4093

SHR-8068 plus adebrelimab and bevacizumab for advanced hepatocellular carcinoma (aHCC): A phase 1b/2 study

[Ver Abstract](#)

ABSTRACT 4099

Cobolimab and dostarlimab in the first-line treatment of unresectable hepatoma: A multi-center, single arm, phase 2 trial

[Ver Abstract](#)

LEAP-002

LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma

[Ver Abstract](#)



GRUPO DE TRATAMIENTO
DE LOS TUMORES DIGESTIVOS